With 59% Institutional Ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) Is a Favorite Amongst the Big Guns

Yahoo FinanceFeb 27 05:56 ET

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

GlobeNewswireFeb 24 09:08 ET

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Yahoo FinanceFeb 12 08:39 ET

SA Asks: Which Big Pharmas Would Be Most Impacted by Higher Tariffs?

Seeking AlphaFeb 1 12:30 ET

Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsJan 27 05:31 ET · Ratings

Express News | Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing

BenzingaJan 23 15:40 ET